Literature DB >> 17482904

Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.

Takashi Iyanagi1.   

Abstract

Enzymes that catalyze the biotransformation of drugs and xenobiotics are generally referred to as drug-metabolizing enzymes (DMEs). DMEs can be classified into two main groups: oxidative or conjugative. The NADPH-cytochrome P450 reductase (P450R)/cytochrome P450 (P450) electron transfer systems are oxidative enzymes that mediate phase I reactions, whereas the UDP-glucuronosyltransferases (UGTs) are conjugative enzymes that mediate phase II enzymes. Both enzyme systems are localized to the endoplasmic reticulum (ER) where a number of drugs are sequentially metabolized. DMEs, including P450s and UGTs, generally have a highly plastic active site that can accommodate a wide variety of substrates. The P450 and UGT genes constitute a supergene family, in which UGT proteins are encoded by distinct genes and a complex gene. Both the P450 and UGT genes have evolved to diversify their functions. This chapter reviews advances in understanding the structure and function of the P450R/P450 and UGT enzyme systems. In particular, the coordinate biotransformation of xenobiotics by phase I and II enzymes in the ER membrane is examined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482904     DOI: 10.1016/S0074-7696(06)60002-8

Source DB:  PubMed          Journal:  Int Rev Cytol        ISSN: 0074-7696


  51 in total

Review 1.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.

Authors:  Antonia H Tolson; Hongbing Wang
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

Review 2.  Enzyme complexity in intermediary metabolism.

Authors:  Emile Van Schaftingen; Maria Veiga-da-Cunha; Carole L Linster
Journal:  J Inherit Metab Dis       Date:  2015-02-21       Impact factor: 4.982

Review 3.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

4.  Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016.

Authors:  Anitha Saravanakumar; Armin Sadighi; Rachel Ryu; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

Review 5.  Glucose-6-phosphate dehydrogenase, NADPH, and cell survival.

Authors:  Robert C Stanton
Journal:  IUBMB Life       Date:  2012-03-20       Impact factor: 3.885

6.  Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Nancy M Hakooz; Mansour A Alghamdi; Rana B Dajani
Journal:  J Pers Med       Date:  2020-01-06

7.  Grape seed proanthocyanidin suppression of breast cell carcinogenesis induced by chronic exposure to combined 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene.

Authors:  Xiaoyu Song; Nalin Siriwardhana; Kusum Rathore; Degui Lin; Hwa-Chain Robert Wang
Journal:  Mol Carcinog       Date:  2010-05       Impact factor: 4.784

8.  Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling.

Authors:  Tacy Santana Machado; Stéphane Poitevin; Pascale Paul; Nathalie McKay; Noémie Jourde-Chiche; Tristan Legris; Annick Mouly-Bandini; Françoise Dignat-George; Philippe Brunet; Rosalinde Masereeuw; Stéphane Burtey; Claire Cerini
Journal:  J Am Soc Nephrol       Date:  2017-12-08       Impact factor: 10.121

9.  Identification of methylmercury tolerance gene candidates in Drosophila.

Authors:  Cecon T Mahapatra; Jeffrey Bond; David M Rand; Matthew D Rand
Journal:  Toxicol Sci       Date:  2010-04-07       Impact factor: 4.849

Review 10.  NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family.

Authors:  Takashi Iyanagi; Chuanwu Xia; Jung-Ja P Kim
Journal:  Arch Biochem Biophys       Date:  2012-09-11       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.